חוב כולל להון IN8bio, Inc (INAB)

IN8bio, Inc. (INAB) is developing innovative methods to combat leukemia and glioblastoma, leveraging B2B collaborations with oncology centers. This daily price action on GURU.Markets, where the indicator stands at 0.11, links the business model to the protection of intellectual property through gene modification patents. The high qualification of the staff of biochemists and clinical trial compliance experts ensures the stability of the company's R&D processes.

This ratio determines the dependence of the financing structure on borrowed funds, comparing total liabilities to net assets to assess the issuer's financial autonomy. Analyzing the proportion of total liabilities relative to equity is critical for IN8bio, Inc. (INAB), as the costs of developing cellular therapies for leukemia and the uncertainty of clinical trial outcomes place a significant burden on the company's balance sheet.